About:
EnPlusOne Biosciences is harnessing the power and flexibility of enzymes to develop RNA therapeutics. There is currently a lot of interest in creating RNA therapeutics but a lack of companies that can generate the diverse forms of RNA efficiently. Using their proprietary ezRNATM platform, EnPlusOne is building RNA enzymatically to promise long-term manufacturing solutions to sustainably deliver RNA therapeutics at scale. These abilities range from de novo RNA synthesis to single RNA extensions off of therapeutic payloads, as well as incorporating a diverse array of nucleotide modifications, all using aqueous-based reaction conditions.